Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tofacitinib in early active axial spondyloarthritis
NCT06112665Phase 4Recruiting
- Sponsor
- Charité – Universitätsmedizin Berlin
- Start
- Nov 2023
- Primary completion
- Mar 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of tofacitinib in axial spondyloarthritis (axSpA), sponsored by Charité – Universitätsmedizin Berlin. Started Nov 2023; status: recruiting.
02
Drugs
03
Conditions
axial spondyloarthritis (axSpA)
Beyond the preview
Go deeper on NCT06112665.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06112665.